XCellCure

XCellCure is a private, commercial-stage diagnostics company headquartered in St. Louis, Missouri, with a mission to transform the treatment of acute coronary syndromes. Its core product, the AMiAware Cardiac Panel, is a multiplexed diagnostic test designed to non-invasively identify patients at high risk for a heart attack, allowing for timely, personalized therapeutic intervention. The company targets the significant unmet need in preventing first and fatal heart attacks, aiming to move acute cardiovascular care into the realm of precision medicine. XCellCure appears to be in an early revenue-generating phase, commercializing its patented prognostic markers to clinics and healthcare providers.

Patented multiplexed diagnostic assay measuring 13 novel cardiovascular biomarkers to generate a patient-specific 'Signature of Disease' for predicting impending heart attacks.

XCellCure competes in the cardiac biomarker space against established lab tests (e.g., high-sensitivity troponin, CRP) and integrated risk scores. It also faces competition from larger, well-capitalized diagnostics companies (e.g., Abbott, Roche, Siemens Healthineers) that have extensive portfolios and sales forces in cardiology.